Carmen Allegra, M.D.

Carmen J Allegra, M.D. - Research & Publications

(352) 265-0725

Request an Appointment

Publications

Rectal cancer patients younger than 50 years lack a survival benefit from NCCN guideline-directed treatment for stage II and III disease.
Cancer
2018

Molecular Subtypes of Colorectal Cancer in Pre-Clinical Models Show Differential Response to Targeted Therapies: Treatment Implications Beyond Kras Mutations
Plos One
2018

Rectal cancer patients younger than 50 years lack a survival benefit from NCCN guideline-directed treatment for stage II and III disease.
Cancer
2018

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology
Journal of Clinical Oncology
2017

Molecular Biomarkers for the Evaluation of Colorectal Cancer Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology
Archives of Pathology & Laboratory Medicine
2017

Clinical Outcome From Oxaliplatin Treatment in Stage II/III Colon Cancer According to Intrinsic Subtypes Secondary Analysis of Nsabp C-O7/Nrg Oncology Randomized Clinical Trial
Jama Oncology
2016

Extended Ras Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015
Journal of Clinical Oncology
2016

Analysis of 320 Gastroenteropancreatic Neuroendocrine Tumors Identifies Ts Expression as Independent Biomarker for Survival
International Journal of Cancer
2014

Nsabp Fc-6: Phase II Study To Determine Surgical Conversion Rate in Patients (Pts) Receiving Neoadjuvant (Na) Mfolfox7 Plus Dose-Escalating Cetuximab (C) for Unresectable K-Ras Wild-Type (Wt) Colorectal Cancer With Metastases (Mcrc) Confined To the Liver
Annals of Surgical Oncology
2014

Aflibercept Versus Placebo in Combination With Fluorouracil, Leucovorin and Irinotecan in the Treatment of Previously Treated Metastatic Colorectal Cancer: Prespecified Subgroup Analyses From the Velour Trial
European Journal of Cancer
2014

Mean Overall Survival Gain With Aflibercept Plus Folfiri Vs Placebo Plus Folfiri in Patients With Previously Treated Metastatic Colorectal Cancer
British Journal of Cancer
2013

Bevacizumab in Stage Ii-III Colon Cancer: 5-Year Update of the National Surgical Adjuvant Breast and Bowel Project C-08 Trial
Journal of Clinical Oncology
2013

Addition of Aflibercept To Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With An Oxaliplatin-Based Regimen
Journal of Clinical Oncology
2012

Aflibercept/Folfiri (Af) Vs Placebo/Folfiri (Pf) in Metastatic Colorectal Cancer (Mcrc): Post-Hoc Analysis of Survival Excluding Adjuvant (Adj)-Only Patients in the Velour Trial
Annals of Oncology
2012

Sensitivity Analyses of Progression-Free Survival (Pfs) of Aflibercept-Folfiri Versus Placebo-Folfiri in Metastatic Colorectal Cancer (Mcrc): Results From the Velour Study
Annals of Oncology
2012

Aflibercept Versus Placebo in Combination With Folfiri in Previously Treated Metastatic Colorectal Cancer: Mean Overall Survival for Subgroups From Velour
Annals of Oncology
2012

Association of Obesity With Dna Mismatch Repair Status and Clinical Outcome in Patients With Stage Ii Or Iii Colon Carcinoma Participating in Ncctg and Nsabp Adjuvant Chemotherapy Trials
Journal of Clinical Oncology
2012

Alternative End Points To Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time To Failure of Strategy-An Aide Et Recherche En Cancerologie Digestive Group Study
Journal of Clinical Oncology
2011

Oxaliplatin as Adjuvant Therapy for Colon Cancer: Updated Results of Nsabp C-07 Trial, Including Survival and Subset Analyses
Journal of Clinical Oncology
2011

Intravenous (Iv) Aflibercept Versus Placebo in Combination With Irinotecan/5-Fu (Folfiri) for Second-Line Treatment of Metastatic Colorectal Cancer (Mcrc): Results of a Multinational Phase III Trial (Efc10262-Velour).
Annals of Oncology
2011

Combination Therapy for Renal Cell Cancer: What Are Possible Options?
Oncology
2011

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of Nsabp Protocol C-08
Journal of Clinical Oncology
2011

Effective salvage treatment of recurrent Ewing sarcoma utilizing chemotherapy and zoledronic acid.
Clinical Advances in Hematology and Oncology
2010

Initial Safety Report of Nsabp C-08: a Randomized Phase III Study of Modified Folfox6 With Or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II Or III Colon Cancer
Journal of Clinical Oncology
2009

The Marriage of Growth Factor Inhibitors and Chemotherapy: Bliss Or Bust?
Journal of Clinical Oncology
2009

Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
Journal of Clinical Oncology
2009

Don Quixote and the Quest for Personalized Medicine
Journal of Clinical Oncology
2008

Research Interests

His primary research effort is focused on developing new therapeutic strategies for patients with GI malignancies through the identification and translation of novel laboratory discoveries and therapeutic agents. This work is underpinned by new target discovery and identification of prognostic and predictive signatures required to personalize oncologic therapeutics.